TLDR
- UNH stock is up more than 20% year-to-date and 39% over the past six months
- Medical care ratio improved to 85.3% from 87.1% a year earlier, with medical costs down 2% to $148.8 billion
- 2026 EPS estimate stands at $19.82, reflecting 21% year-over-year growth
- Wall Street holds a Strong Buy consensus with an average price target of $481.67, implying 21% upside
- UnitedHealthcare is cutting 30% of remaining prior authorization requirements
UNH stock currently trades around $397, up more than 20% year-to-date and roughly 39% over the past six months. That run has outpaced the S&P 500’s 12% gain over the same stretch.
UnitedHealth Group Incorporated, UNH
The recovery is being driven by easing medical cost pressures. In the first half of 2026, UnitedHealth’s medical care ratio dropped to 85.3% from 87.1% a year earlier. Total medical costs fell 2% to $148.8 billion.
The company has also been pulling back from lower-return businesses. UNH is exiting certain Medicare Advantage and Optum Health markets to cut losses and redirect capital toward more profitable areas.
Capital returns have added to investor confidence. Through mid-July 2026, UNH had repurchased $4 billion of stock and remains on track to buy back at least $5 billion for the full year. It also paid $4.1 billion in dividends in the first half.
Prior Authorization Changes
UnitedHealthcare announced it is removing 30% of its remaining prior authorization requirements, covering surgeries, diagnostic tests, and therapies. The move is expected to reduce administrative friction and improve member satisfaction.
The trade-off is real, though. Fewer checks could push up healthcare utilization and lift medical costs. Management will need its pricing and care management approach to absorb any increases.
Earnings Outlook
The Zacks consensus estimate for 2026 EPS is $19.82, up 21.2% year-over-year. That estimate has received two upward revisions in the past month with no downward moves.
For 2027, EPS is projected to grow another 13.7% to $22.54, with revenue rising 2.6% to $458.33 billion. UNH has beaten earnings estimates in each of the past four quarters, with an average surprise of 12.1%.
On valuation, UNH trades at 18.51x forward earnings, above the industry average of 16.13x but still below its own five-year median of 19.11x.
Bernstein analyst Lance Wilkes reiterated a Buy rating last week with a $512 price target. He highlighted Optum Insight as a key long-term growth driver, particularly for AI-powered healthcare operations.
Not everyone is fully on board. Erste Group analyst Hans Engel recently downgraded UNH to Hold, citing revenue growth in 2026 and 2027 that he sees as low relative to sector peers, combined with a stretched valuation multiple.
Wall Street overall carries a Strong Buy consensus on UNH, with 16 Buy ratings and five Holds. The average price target of $481.67 implies about 21% upside from current levels.
The April CMS decision to raise 2027 Medicare Advantage payments by an average of 2.48%, well above the initially proposed 0.09%, also gave the reimbursement picture a boost.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
